The company is seeking expedited FDA approval for a higher 7.2 mg dose of its weight-loss drug Wegovy after strong study results. It also received positive news as Medicare negotiated a 71% discount for its weight-loss drugs, making them more accessible. Furthermore, promising phase II data for a new drug, amycretin, showed significant weight loss and blood sugar benefits. However, analysts have recently reduced their consensus price target, reflecting a mix of optimism for its strategic pipeline and caution regarding near-term pressures.